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Objectives This study sought to evaluate the safety and feasibility of zotarolimus-eluting stent implantation in focal athero-
sclerotic lesions of the internal pudendal arteries among men with erectile dysfunction (ED) and a suboptimal
response to phosphodiesterase-5 inhibitors.
Background ED, a common condition, is often mediated by atherosclerosis. Current treatment options are limited.
Methods Male subjects with atherosclerotic ED and a suboptimal response to phosphodiesterase-5 inhibitors were en-
rolled in this prospective, multicenter, single-armed safety and feasibility trial. A novel combination of clinical,
duplex ultrasound, and invasive angiographic factors were used to determine eligibility for stent therapy. The
primary safety endpoint was any major adverse event 30 days after the procedure. The primary feasibility end
point was improvement in the International Index of Erectile Function (Erectile Dysfunction Domain) score 4
points in 50% of subjects at 3 months. We report 6-month follow-up results, including duplex ultrasound and
angiography.
Results Forty-five lesions were treated with stents in 30 subjects. Procedural success was 100% with no major adverse
events through follow-up. The primary feasibility endpoint at 6 months was achieved by 59.3% of intention-to-
treat subjects (95% confidence interval: 38.8% to 77.6%) and 69.6% of per-protocol subjects (95% confidence
interval: 47.1% to 86.8%). Duplex ultrasound peak systolic velocity of the cavernosal arteries increased from
baseline by 14.4  10.7 cm/s at 30 days and 22.5  23.7 cm/s at 6 months. Angiographic binary restenosis
(50% lumen diameter stenosis) was reported in 11 (34.4%) of 32 lesions.
Conclusions Among patients with ED and limited response with pharmacologic therapy, percutaneous stent revascularization
of the internal pudendal artery is feasible and is associated with clinically meaningful improvement in both sub-
jective and objective measures of erectile function. (Safety and Feasibility of the Zotarolimus Stent in Treating
Males With Erectile Dysfunction (ED) (ZEN); NCT01643200). (J Am Coll Cardiol 2012;60:2618–27) © 2012 by
the American College of Cardiology Foundation
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December 25, 2012:2618–27 Drug-Eluting Stenting for Erectile DysfunctionErectile dysfunction (ED) is defined as the recurrent inabil-
ity to achieve and maintain an erection satisfactory for
sexual intercourse (1). Successful treatment of ED has a
strong impact on quality of life (2,3). More than 150 million
men worldwide have ED, and 52% of men in the United
States 40 to 70 years of age report some degree of ED (4,5).
ED is managed by identifying and treating any reversible
causes, followed by an oral phosphodiesterase-5 inhibitor
(PDE5i) trial. However, up to 50% of men have a subop-
timal response to PDE5i therapy, and because subsequent
therapies tend to be more intrusive (such as penile injection
therapy with vasodilators, vacuum pump therapy, or penile
implants), there is a need for additional therapies (6). It is
well known that ED and coronary artery disease share
common vascular risk factors such as age, diabetes,
hypertension, dyslipidemia, and tobacco use (7–9). These
factors contribute to ED through consequent endothelial
dysfunction, abnormal vasomotion, and atherosclerosis.
The presence of ED significantly increases the risk of
developing cardiovascular disease, and up to 70% of men
with new-onset angina and angiographically documented
coronary artery disease have a history of antecedent ED
(10–13).
See page 2628
Restoring adequate arterial inflow in patients with penile
arterial insufficiency can improve erectile function. Surgical
revascularization has been used successfully in younger men
after blunt perineal trauma or pelvic fracture (14). Older
subjects can have obstructive atherosclerotic disease identi-
Figure 1 Study Enrollment Flowchart
ED  erectile dysfunction; EDV  end diastolic velocity; IIEF  International Indexfied by angiography in the iliac,
internal pudendal, and cavernosal
arteries (15–19). Although endo-
vascular revascularization with bal-
loon angioplasty has resulted in at
least short-term improvement of
erectile function, there have been no
prior reports on the feasibility of
endovascular stents for ED (18).
We conducted the first-in-man
ZEN (Zotarolimus-Eluting Pe-
ripheral Stent System for the
Treatment of Erectile Dysfunction
in Males with Suboptimal Re-
sponse to PDE5 Inhibitors) trial
examining the safety and feasibility
of using a balloon-expandable pe-
ripheral drug-eluting stent (DES)
to treat selected patients with atherosclerotic ED and unilateral
or bilateral focal internal pudendal artery (IPA) stenoses.
Methods
Protocol overview. Subjects were screened at 16 centers in
the United States. The institutional review board approved
the study at each site and informed consent was obtained
from all subjects. A multidisciplinary team consisting of a
urologist with expertise in sexual medicine and a vascular
interventional specialist evaluated all subjects.
Subject enrollment and attrition is illustrated in Figure 1.
Key inclusion criteria were: 1) men 18 years of age or older
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
DUS  duplex ultrasound
ED  erectile dysfunction
IIA  internal iliac artery
IIEF  International Index
of Erectile Function
IPA  internal pudendal
artery
PDE5i 
phosphodiesterase-5
inhibitor
PSV  peak systolic
velocity
ctile Function; PSV  peak systolic velocity; SEP  Sexual Encounter Profile.of Ere
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Drug-Eluting Stenting for Erectile Dysfunction December 25, 2012:2618–27in an active sexual relationship with 1 partner 6 months;
2) suboptimal response to PDE5i therapy, as documented by a
4-week run-in phase; 3) reduced cavernosal arterial penile flow
with duplex ultrasound (DUS) peak systolic velocity (PSV) of
the right and left cavernosal arteries 30 cm/s; 4) cavernosal
rtery anteroposterior and transverse diameter at mid-shaft0.3
m; and 5) angiographic stenosis of one or both IPA with
arget vessel reference diameter(s) 2.25 mm and 4.20 mm
y visual estimation and primary lesion length(s) 27 mm.
ey exclusion criteria were: 1) any nonvascular cause of ED
i.e., prostatectomy, pelvic radiation, pelvic trauma, Pey-
onie’s disease, hormonal, psychogenic, etc.); 2) untreated
ypogonadism (serum total testosterone 300 ng/dl within
days before enrollment); 3) diabetes mellitus with glyco-
ylated hemoglobin levels 8%; 4) chemotherapy in the
rior 12 months or life expectancy of fewer than 12 months;
) myocardial infarction, cardiovascular accident, life-
hreatening arrhythmia, or unstable angina requiring hos-
italization within 3 months before enrollment, or any
ubject actively receiving nitrate therapy; 6) bleeding dia-
hesis or known hypercoagulable state; 7) penile veno-
cclusive dysfunction (venous leak) by DUS with right or
eft cavernosal artery end-diastolic velocity 5 cm/s; 8)
erum creatinine levels2.5 mg/dl; and 9) nontarget lesions
f the common iliac artery, IIA, or common penile artery
70%.
nternational index for erectile function and the sexual
ncounter profile. The International Index for Erectile
unction (IIEF) (20) and Sexual Encounter Profile (21)
uestionnaires have been validated in numerous previous
linical trials as useful instruments for measuring efficacy of
D interventions (22). Eligible subjects first were provided
ith a baseline IIEF questionnaire consisting of 15 ques-
ions divided into the following 5 domains: erectile func-
ion, orgasmic function, sexual desire, intercourse satisfac-
ion, and overall satisfaction. We used the IIEF-6 domain
core, which is a subset of 6 questions specific to erectile
unction (score range: 1 to 30). The IIEF-6 questionnaire
as been shown to discriminate highly between men with
nd without ED with an optimal cutoff score 21 for
stablishing ED diagnosis (20). A baseline IIEF-6 score of
6 and 21 was required before proceeding to a 4-week
un-in phase, during which time at least 4 attempts at
ntercourse were required while the patient was taking
DE5i.
After each attempt at intercourse, the subject completed
he Sexual Encounter Profile diary. On completion of the
-week run-in phase, subjects continued with the screening
rocess if they responded “No” to question 3 (“Did your
rection last long enough for you to have successful inter-
ourse?”) at least 50% of the time. Subjects then took a
econd IIEF assessment to evaluate his response to the
-week run-in on PDE5i treatment, and if the IIEF-6
omain score remained at 6 and 21, they qualified to
ndergo further screening. cenile duplex ultrasonography. Penile DUS was per-
ormed following a standardized protocol with a pharma-
ologically induced erection via direct injection of intracav-
rnosal alprostadil (10 to 40 g). After visual or manual
stimulation as required to achieve maximal erection, the
subject’s cavernosal artery diameters and PSV were as-
sessed for eligibility. End diastolic velocities were as-
sessed at peak erection. An insonation angle of 60
degrees was required, and the standardized protocol and
all DUS studies were interpreted by a core laboratory
(VasCore, Massachusetts General Hospital, Boston,
Massachusetts). If subjects met ultrasound criteria, they
then were scheduled for angiography with possible
intervention.
Invasive angiography. Angiography was performed to de-
fine the anatomic features of all erectile-related arteries (Fig. 2).
A pharmacologically induced partial erection was recom-
mended and was obtained by injecting 10 to 40 g of
intracavernosal alprostadil. Anteroposterior projections
were used for the distal aorta and common iliac arteries,
contralateral projections for the internal iliac origins, ipsi-
lateral cranial views for the IPA origins, and anteroposterior
or ipsilateral straight oblique or caudal angulations were best
for visualizing the body and distal IPA. Subjects could
proceed with investigational stent therapy if the visual
estimate demonstrated an IPA lesion length 27 mm and
either: 1) unilateral stenosis70% and100% with contralat-
eral vessel stenosis 50% (or stenosis 50% and 100% if
ontralateral vessel was 100% occluded); or 2) bilateral stenosis
50% and 100% in each vessel. The intent of these angio-
raphic inclusion criteria was to include subjects with severe
nilateral (in the presence of mild or occluded contralateral
essel disease) or moderate to severe bilateral IPA disease.
ubjects were excluded if there was70% stenosis of non-IPA
rectile-related arteries.
Quantitative angiography (CMS, Leiden, the Nether-
ands) was performed by observers in an angiographic core
aboratory (Beth Israel Deaconess Medical Center, Boston,
assachusetts) who were unaware of the clinical outcomes.
he proximal and distal reference vessel diameter and the
inimal lumen diameter were used to determine the percent
iameter stenosis before and after the procedures and at the
-month follow-up. Binary restenosis was defined as 50%
iameter stenosis on follow-up angiography. Acute gain was
efined as the increase in the minimal lumen diameter from
he baseline to the post-procedure angiogram; late lumen
oss was defined as the loss in minimal lumen diameter from
he post-procedural to the follow-up angiogram. Stent
ntegrity was defined as the absence of stent fracture or
eformation during the follow-up period.
tent device and interventional procedure. The Resolute
otarolimus-Eluting Stent System (Medtronic, Santa Rosa,
alifornia) is composed of a cobalt-chromium alloy plat-
orm coated with a biocompatible tripolymer (Biolinx)
ontaining the antiproliferative agent zotarolimus at a con-
entration of 1.6 g/mm2. Zotarolimus, a tetrazole-
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December 25, 2012:2618–27 Drug-Eluting Stenting for Erectile Dysfunctioncontaining macrocyclic immunosuppressant, is eluted over
180 days. Because the IPA has a smaller average diameter
(approximately 2.6 mm in this study), a DES was chosen
over bare-metal stent in hopes of minimizing restenosis
rates. Available stent sizes range from 2.25 to 4.0 mm in
diameter and 8 to 30 mm in length.
On confirmation of angiographic eligibility, subjects re-
ceived heparin to achieve an activated clotting time 250 s
before and during stent placement. All subjects received 325
mg aspirin within 24 h of the procedure and daily thereafter
for at least 6 months. A loading dose of clopidogrel 300
mg (or ticlopidine if allergic) was given periprocedurally,
and clopidogrel 75 mg daily was required for 6 months. Use
of any PDE5i within 36 h of the procedure was prohibited,
and PDE5i use was resumed in follow-up at investigator
discretion as clinically required. In general, single femoral
vascular access was performed to treat both the ipsilateral
and contralateral IPA. A guiding catheter or sheath was
brought into or near the IPA origin, and the lesion was
crossed with a 0.014-inch guidewire and was treated using
standard interventional techniques. Pre-dilatation with a
balloon catheter less than or equal to the reference diameter
of the artery was performed, and direct stenting was not
allowed. This was to provide adequate lesion assessment and
preparation before stent placement. Target lesions were
treated with a single stent whenever possible, but up to 2
stents could be placed in an overlapping manner to cover
longer lesions up to 27 mm or multiple lesions (provided the
Figure 2 Vascular Inflow Anatomy Required for Normal Erectile
Arterial inflow of the penis is depicted. Proximal inflow includes the distal aorta, comm
of the bilateral internal pudendal arteries (IPA), which are branches of the IIA. The dist
sion of Medtronic Inc.primary lesion met angiographic eligibility) or to cover anystent-edge dissections. The study protocol limited the use of
stents to 2 per IPA and to no more than 4 total per subject.
Post-dilation was not required and was performed at oper-
ator discretion. The procedure was considered a failure if the
stent could not cross the target lesion after adequate
pre-dilation.
Study endpoints. The primary safety endpoints were major
adverse events at 30 days defined as device- or procedure-
related death, or both; occurrence of perineal gangrene or
necrosis (glans penis, penile shaft, scrotal or anal); or the
need for subsequent perineal, penile, or anal surgery (in-
cluding target lesion or vessel revascularization or arterial
embolization procedures). The primary feasibility endpoint
was obtained at 3 months and was defined as improvement
in erectile function from pre-procedure of the IIEF-6 score
by 4 points in 50% of subjects. A change of 4 points
in the IIEF-6 score has been shown to be the minimal
clinically important difference for assessing a meaningful
change in erectile function and has been validated across a
broad spectrum of ED therapies (23). An improvement in at
least 50% of subjects was chosen empirically as a reasonable
goal for therapy.
Secondary endpoints included the major adverse event
rate at 3 and 6 months; changes in sexual function from
pre-procedure as assessed by the IIEF at 30 days and 6
months; mean PSV as assessed by DUS in the right and left
cavernosal arteries at the mid-shaft during pharmacologi-
cally induced erection within 30 days and 6 months, and 12
tion
c artery, and internal iliac arteries (IIA). The longest inflow segments consist
supply the cavernosal, dorsal penile, and urethral arteries. Reprinted with permis-Func
on ilia
al IPAmonths post-procedure; restenosis and stent integrity as
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Drug-Eluting Stenting for Erectile Dysfunction December 25, 2012:2618–27assessed by angiography at 6 months. Claudication by
vascular territory was assessed by change in Rutherford
class. The Harvard Clinical Research Institute (Boston,
Massachusetts) coordinated an independent data monitor-
ing committee, which reviewed any adverse events reported
during the conduct of the study. All subjects will be
followed up yearly for 5 years.
Statistical analysis. Descriptive statistics were performed,
ncluding frequencies and mean  SD. To test for predic-
ors of binary restenosis at the 6-month follow-up, a
nivariate analysis was performed on demographic variables,
edical history and risk factors, procedure and lesion
haracteristics, and pre-procedure IIEF total score. A p
alue  0.05 was considered statistically significant. SAS
oftware version 9.1 (SAS Institute, Cary, North Carolina)
as used for all analyses.
esults
emographics. A total of 30 subjects had 45 stents placed.
he enrollment flowchart (Fig. 1) illustrates subject screen-
ng and enrollment details. The most common DUS exclu-
ions were adequate arterial inflow and venous leak. Of 89
ubjects who underwent angiography, approximately one-
hird were found to have insufficient disease (n  29,
2.5%), and one third had excessive disease (n  30,
3.7%).
Baseline demographics are reported in Table 1. The mean
ge was 60.1 years (range: 43 to 77 years). Although many
ubjects had known cardiovascular risk factors, most subjects
ad no history of ischemic heart disease. These distributions
ay reflect that patients were identified from both cardio-
ascular and urologic practice settings.
Baseline Demographics of Subjects UndergoingInternal Pudendal Artery Stenting (n  30)Table 1 Baseline Demographics of Subjects UndergoingInternal Pudendal Artery Stenting (n  30)
age  SD, yrs 60.1 7.7
Medical history and risk factors, no. (%)
History of myocardial infarction 6 (20.0)
History of stroke 4 (13.3)
History of life-threatening arrhythmia 2 (6.7)
History of unstable angina 2 (6.7)
History of benign prostatic hyperplasia 6 (20.0)
Lower urinary tract symptoms 6 (20.0)
Current nitrate therapy 0 (0.0)
History of tobacco use
Never 9 (30.0)
Former 12 (40.0)
Current 9 (30.0)
Alcoholism 1 (3.3)
History of recreational drug use
Never 19 (63.3)
Former 10 (33.3)
Current 1 (3.3)
Subjects with baseline Rutherford class  1 4 (13.3)vValues are mean  SD or n (%).rocedure and lesion characteristics. Mean hospital stay
as 0.5  0.5 days, and mean procedure duration was 102.5 
4.9 min. There were no deaths during the study. Angio-
raphic lesion characteristics are described in Table 2. The
ean lesion length was 17.6  9.9 mm (range: 2.47 to
5.88 mm), 33 of 45 lesions (73.3%) were eccentric, and no
esion was ulcerated or thrombotic. Mild or no calcification
as seen in 44 lesions (97.8%), moderate calcification was
een in 1 lesion (2.2%), and no lesions were severely
alcified.
Procedural success was 100%. Target lesions were most
revalent in the distal IPA (24 lesions, 53.3%), followed by
lesions in the ostial IPA (13.3%), 5 proximal IPA lesions
11.1%), and 4 lesions in the mid-IPA (8.9%). Post-stent
alloon dilatation was performed in 50% of lesions, with a
ean nominal balloon diameter of 2.7  0.4 and a mean
aximal stent balloon pressure of 15.0  3.7 atmospheres.
case example is shown in Figure 3.
rimary and secondary endpoints. The primary safety
ndpoint at 30 days was met in all subjects and there were
o subsequent safety events during the 6 months of follow-
p. In the intention-to-treat analysis, the primary feasibility
ndpoint (IIEF improvement of 4 points) at 3 months
as achieved in 59.3% (95% confidence interval [CI]: 38.8%
o 77.6%) of 27 reported subjects at 3 months and was
nchanged at 6 months. In the per-protocol analysis at 3
onths, 68.2% (95% CI: 45.1% to 86.1%) of subjects were
bserved to have IIEF improvement of 4 points, and at 6
onths, 69.6% (95% CI: 47.1% to 86.8%) of per-protocol
ubjects showed IIEF improvement (Table 3).
The per-protocol analysis excluded 5 subjects who were
bserved by the core laboratory to have lesions in pelvic
rteries other than the IPA (2 obturator arteries, 2 middle
ectal arteries, and 1 inferior gluteal artery), resulting in a
er-protocol cohort size of 25 subjects. Given the first-in-
an nature of this protocol and the variability of pelvic
ascular anatomic features, inadvertent stenting of a
ontarget vessel was not unexpected. However, there
ere no safety issues identified with stenting non-IPA
Angiographic Lesion Characteristics Before theProcedure, Immediately After the Proc dure,a d at 6 Months After the P ocedu e(45 Lesions in 30 Subjects)
Table 2
Angiographic Lesion Characteristics Before the
Procedure, Immediately After the Procedure,
and at 6 Months After the Procedure
(45 Lesions in 30 Subjects)
Angiographic Quantitative
Analysis
Before the
Procedure
Immediately
After the
Procedure
6 Months After
the Procedure
Reference vessel diameter
(mm)
2.63  0.43 — 2.48  0.35
Lesion length (mm) 17.55  9.94 — —
Lesion MLD (mm) 0.96  0.41 2.08 0.51 1.49 0.56
Lesion percent stenosis (%) 63.28 14.88 23.25 10.78 40.14 20.40
Acute gain (mm) — 1.13 0.54 —
Late lumen loss — — 0.56 0.57
Values are mean /- SD. MLD  minimum luminal diameter.essels seen through 6 months of follow-up. Two subjects
2623JACC Vol. 60, No. 25, 2012 Rogers et al.
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follow-up at 3 months, but both subjects returned for
follow-up at 6 months. One subject declined follow-up at
6 months.
Secondary endpoints are shown in Table 3. There were
no stent fractures seen in follow-up.
The total change in IIEF domain score from pre-
procedure to 6 months was 12.5 (95% CI: 6.1 to 19.0). The
incremental change of IIEF and PSV over time is illustrated
Figure 3 A 60-Year-Old Man With a History of Coronary Artery
and ED With a Poor Response to Phosphodiesterase-5
Duplex ultrasonography was performed of the left and right cavernosal arteries. (A
18 cm/s, and (B) the PSV improved at 30 days after the procedure to 36 cm/s. (
(D) the PSV improved 30 days after the procedure to 36 cm/s. On angiography, (E
the left distal IPA (arrow) just before the bifurcation into the scrotal branches (low
fully with 2 resolute zotarolimus-eluting stents (arrows). The subject’s total IIEF sc
primary end point of IIEF improvement of 4 points. Abbreviations as in Figures 1in Figure 4. The mean angiographic percent stenosis pre-procedure (number of lesions: 45), post-procedure (number
of lesions: 45), and at 6 months (number of lesions: 32) was
63.3%, 23.3%, and 41.4%, respectively. The mean change in
PSV from baseline was 14.4  10.7 cm/s at 30 days and
22.5  23.7 cm/s at 6 months.
Binary restenosis was seen in 11 (34.4%) of 32 lesions.
Univariate analysis of baseline procedural and demographic
variables did not identify any statistically significant predic-
tors of binary restenosis at 6 months. At baseline, 4 (13.3%)
se, Percutaneous Coronary Intervention,
bitor
systolic velocity (PSV) of the right cavernosal artery before the procedure was
ilarly, PSV of the left cavernosal artery before the procedure was 25 cm/s, and
patient was found to have a chronically occluded right IPA and a severe lesion of
nch) and common penile artery (upper branch), which (F) was treated success-
reased by 13 points at 6 months, and the subject also achieved the 3-month
.Disea
Inhi
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Drug-Eluting Stenting for Erectile Dysfunction December 25, 2012:2618–27the 3-month and 6-month follow-up, 3 (10%) of 30 subjects
had a Rutherford classification of 1. The percentage of
ubjects who were compliant with follow-up visits at 30 days
n  30), 3 months (n  30), and 6 months (n  28) was
3.3%, 80.0%, and 82.1%, respectively.
Primary and Secondary EndpointsTable 3 Primary and Secondary Endpoints
3 Month
Primary safety endpoint (ITT and PP groups)
Freedom from MAE to 30 days 100%
Primary feasibility endpoint (ITT group)
IIEF improvement 4 points 59.3% (95% CI: 38.8% to
Primary feasibility endpoint (PP group)
IIEF improvement 4 points 68.2% (95% CI: 45.1% to
Secondary endpoints (ITT and PP groups)
Binary restenosis (ITT group) —
Binary restenosis (PP group) —
Stent integrity (ITT group) —
Stent integrity (PP group) —
*Three subjects were unavailable for follow-up at 3 and 6months in the ITT group. †Analysis perform
for follow-up at 3months (n 22); 1 subject returned for follow-up at 6months (n 23). ‡Number o
at 6 months in 10 of 30 subjects in the ITT group and 11 of 32 reported lesions; 2 of these 11 case
the latter of which occurred after stent migration. Binary restenosis was seen in 8 of 26 lesions t
CI  confidence interval; IIEF  International Index of Erectile Function; ITT  intention-to-treat
Figure 4 Results of Total IIEF Score and Duplex PSV Values Ov
Duplex ultrasound (DUS) was not performed at the 3-month follow-up as required b
procedure and at 1 month and 6 months after the procedure. PSV averaged over r
Abbreviations as in Figure 1.iscussion
he ZEN trial is a first-in-man investigation assessing the
afety and feasibility of stenting atherosclerotic IPA lesions
n highly selected subjects. Stenting of the IPA was found to
6 Months
100%
), n  27* 59.3% (95% CI: 38.8% to 77.6%), n  27*
), n  22† 69.6% (95% CI: 47.1% to 86.8%), n  23†
34.4% (95% CI: 18.6% to 53.2%), no. of lesions  32‡
30.8% (95% CI: 14.3% to 51.8%), no. of lesions  26
100.0% (95% CI: 88.8% to 100.0%), no. of lesions  31
100.0% (95% CI: 86.8% to 100.0%), no. of lesions  31
available follow-up. The per-protocol analysis consisted of 25 subjects; 3 subjects were unavailable
s as reported by core laboratory based on available follow-up data. Binary restenosis was observed
ary restenosis were observed on nontarget lesions (left obturator artery and middle rectal artery),
n the PP group.
major adverse event; PP  per-protocol.
me
study protocol; PSV was reported from DUS by the core laboratory before the
nd left cavernosal arteries at the time of peak erection based on available data.s
77.6%
86.1%
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December 25, 2012:2618–27 Drug-Eluting Stenting for Erectile Dysfunctionbe technically feasible and safe and was performed with high
procedural success rates. Many subjects (but not all) re-
ported subjective improvement in erectile function after
these procedures, and there were concomitant increases in
penile flow as determined by DUS. Angiographic follow-up
demonstrated no stent fractures and reasonable binary
patency considering the first-in-man use of a DES in a new
vascular bed.
In addition to intact neurovascular, hormonal, and struc-
tural mechanisms, initiation and maintenance of erection
depends not only on adequate arterial inflow but also on
veno-occlusive function. That is, blood should enter the
cavernosal bodies, which then enlarge and compress the
emissary veins, preventing venous leakage during erection. If
venous leak is present, adequate erection may not occur even
in the presence of adequate arterial inflow. During ultra-
sound screening for the ZEN trial, venous leak frequently
was encountered, and those subjects were not enrolled.
The importance of adequate arterial inflow to the penis
for initiation and maintenance of erection is well known and
was first described in 1923 by the French surgeon René
Leriche, who observed that aortoiliac occlusion caused
impotence because of failure of perfusion of the corporal
bodies (24). The vascular inflow to the penis necessary for
adequate erectile function requires patency of erectile-
related arteries, which are shown in Figure 2 (18). The
PA is the longest named segment of arterial inflow to
he penis, and the length is approximately 15 cm from its
rigin to the base of the penis. It travels in a neurovas-
ular bundle along with the internal pudendal nerve,
nitially in an inferior and posterior direction inside the
elvis, then exits the pelvis through the inferior aspect of
he greater sciatic foramen, finally entering the pudendal
Alcock’s) canal, where it travels anteriorly and medially
oward the base of the penis. The IPA experiences a
ow-flow state most of the time, interspersed with high-
ow conditions during erection. As such, the IPA may
ave unique physiologic properties that allow it to re-
odel more efficiently and thus be a more rational target
or vascular intervention (25,26). The distal IPA becomes
he common penile artery, which gives rise to the 2 paired
rteries, the cavernosal (deep penile) and dorsal penile
rteries, which are important for tumescence.
Surgical revascularization of penile arterial inflow usually
s reserved for younger patients with a history of trauma and
s performed only in specialized centers (27). Endovascular
evascularization has been described in case reports, mostly
n the 1980s, which used percutaneous transluminal angio-
lasty without stenting of erectile-related arteries in younger
o middle-aged men with ED (28–33). In these reports,
here was no standardized pre-procedure evaluation of ED
ause, and clinical follow-up was short. This literature has
een reviewed in detail elsewhere (18). More recently, the
ANPI (Pelvic Angiography in Non-Responders to
hosphodiesterase-5 Inhibitors) study was the first study to
escribe the angiographic characteristics of pelvic arterialdisease in patients with ED who were nonresponsive to
PDE5i treatment and had suspected coronary artery disease
(17). In this report, the IPAs were found to have athero-
sclerotic narrowings similar to those in the coronary arteries,
and the average IPA vessel diameter was just slightly less
than the average coronary artery diameter.
Although the ZEN trial demonstrated safe and feasible
stenting of the IPA in selected patients with arterial
insufficiency, there was a significant learning curve to the
procedure, and the identification of responders to stent
therapy remains a subject of investigation. Most patients
screened for this trial did not qualify and the main reasons
for exclusion were: 1) excessive or insufficient angiographic
disease; 2) lack of arterial insufficiency by duplex; or 3)
venous leak. The data from the ZEN trial are not sufficient
to warrant widespread adoption of this new technique.
Many questions remain related to patient selection, the
vascular biological features of the IPA, the hemodynamic
and functional consequences of atherosclerotic IPA lesions,
and the longer-term efficacy and durability of stent therapy.
We observed a much higher binary restenosis rate at 6
months (34%) with the Resolute-DES platform than has
been observed in the coronary circulation (9.2% binary
in-stent restenosis in the Resolute US Trial) (34). This
difference highlights the unknowns in applying DES to the
pelvic vasculature. The mechanism by which clinical im-
provement in erectile function persisted at 6 months despite
angiographic binary restenosis in one third of subjects
remains unknown. No relationship between restenosis and
IIEF-6 scores was seen during follow-up, although the
small number of patients precludes any formal statistical
analysis. This phenomenon is not well understood, but may
reflect interim distal vascular remodeling during a period of
increased penile flow (before restenosis). Psychological ben-
efits of the procedure also may play a role, although these
would be expected to diminish over time. Further, because
of variability in pelvic anatomic features, the IPA was not
always readily identifiable, and 5 subjects had non-IPA
vessels stented with no adverse consequences. It is possible
that computed tomography angiography before performing
invasive angiography could be useful to delineate pelvic
vascular anatomic features (35–37). Approximately one
third of subjects had excessive atherosclerotic or diffuse
disease by angiography that precluded stent therapy. The
efficacy of angioplasty alone or drug-eluting balloons war-
rants further study in this subgroup. Another one third of
subjects undergoing screening angiography were found to
have minimal or no angiographic atherosclerotic disease.
These individuals may have vascular remodeling of their
IPA that may confer increased vascular inflow resistance
during high-flow states (38).
Study limitations. These data represent a first-in-man
experience and reflect intrinsic variability in case selection
and stent deployment technique. There is no control arm,
although the minimal clinically important difference has
been well validated as a measure of clinical efficacy for ED
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DUS examinations were not interpretable formally by the
core laboratory because of the early learning curve by the
sites related to the required Doppler angle of insonation.
Conclusions
Drug-eluting stent therapy for atherosclerotic ED in se-
lected patients who have not responded to PDE5i therapy is
safe and feasible, can improve arterial inflow, and can result
in improvement of erectile function. Defining appropriate
patient selection undoubtedly will be crucial to the success
of any endovascular approach. Patients with longstanding
ED, veno-occlusive disease, or severe diffuse arterial disease
likely will not be candidates for current endovascular ther-
apies. Randomized trials are needed to assess efficacy of this
new technique against the best existing therapies. Finally,
the true prevalence of stenoses amenable to percutaneous
therapy in patients with ED currently is not known, and
further investigations are needed.
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